UPC CFI 2822/2026

Vor dem UPC: BioNTech Group (21 Verfahren)·Promosome LLC (15 Verfahren)

• 2026-09-28
  other

  Zusammenfassung: Decision in cost proceedings after the Munich LD merits decision of 7 July 2026 (EP 2 401 365 revoked, Promosome's infringement actions dismissed): Promosome and The Scripps Research Institute are ordered jointly and severally to pay each defendant group (BioNTech, defendants 1-5; Pfizer, defendants 6-9) EUR 750,000 in recoverable costs, as agreed, satisfied by release of the EUR 1.5m security for costs deposited under the order of 9 April 2025; the cost proceedings close on transfer.

  Rechtsfragen anzeigen (3)

  • Cost decision under R. 150, 151 and 156.3 RoP following an agreed flat-fee reimbursement
  • Release of security for costs to satisfy a costs award (R. 352.2 RoP by analogy)
  • No costs decision for the cost proceedings themselves